Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$153.20 USD

153.20
6,595,457

-13.41 (-8.05%)

Updated May 28, 2024 04:00 PM ET

After-Market: $153.79 +0.59 (0.39%) 5:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

John Blank headshot

Think Suppression, Not Recession: Global Week Ahead

Friday's U.S. nonfarm jobs report will be one for the record books. Before it arrives, Zacks Chief Strategist cautions: This is the mark of suppression, not recession. The choice of words does matter.

Remdesivir Gets Emergency Approval: What's In Store for Gilead?

In a short span of time, Gilead's Remdesivir has been successful in treating some coronavirus patients. But will this give a boost to the pharmaceutical giant?

The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna

The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna

Vertex (VRTX) Q1 Earnings Beat, Trikafta Drives CF Revenues

Vertex (VRTX) rides high on earnings and revenue beat in Q1.The company raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.

Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moderna (MRNA) is a Great Momentum Stock: Should You Buy?

Does Moderna (MRNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Ritujay Ghosh headshot

Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat

A large number of biotech companies have been working on developing drugs and vaccine for the novel coronavirus that has infected more than 3,100,000 and claimed 227,000 lives.

Sweta Jaiswal, FRM headshot

Healthcare ETFs to Gain on Progress in Coronavirus Vaccine

The healthcare space is heated up with players rushing to come up with a vaccine for COVID-19.

The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax

The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax

Moderna (MRNA) Stock Moves -0.35%: What You Should Know

Moderna (MRNA) closed the most recent trading day at $47.88, moving -0.35% from the previous trading session.

3 Stocks to Benefit From Race to Develop Coronavirus Vaccines

Pharmaceutical companies and scientists are relentlessly working on developing coronavirus vaccines and the progress in trails has helped stocks to rally.

Pfizer/BioNTech to Begin Coronavirus Vaccine Study in Germany

Pfizer (PFE) and BioNTech receive approval from regulatory authority in Germany to start an early-stage clinical study to evaluate their mRNA-based vaccine candidates for COVID-19.

Vaxart Up on Pre-Clinical Data on Coronavirus Vaccine Candidates

Vaxart's (VXRT) several COVID-19 vaccine candidates generate immune responses in pre-clinical studies. Stock rises.

Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

Sweta Killa headshot

Coronavirus Makes Biotech ETFs Red Hot

The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.

Company News for Apr 20, 2020

Companies In The News Are: TROX, MRNA, PLNT and PG

The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly

The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly

Ritujay Ghosh headshot

Gilead Increases Enrollment Target, Pharma Rally Continues

Substantial progress has been made over the past few weeks with pharmaceutical companies speeding up development of coronavirus vaccines.

Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?

Is (MRNA) Outperforming Other Medical Stocks This Year?

Moderna Rallies on US Government Grant for Coronavirus Vaccine

Moderna (MRNA) gets a commitment of up to $483 million from the U.S. Government Agency BARDA to accelerate the development of its mRNA-based coronavirus vaccine.

Nalak Das headshot

Buy 5 Top Medical Stocks on Coronavirus Drug Trial Results

The whole world has pinned hopes on pharmaceutical and biotech companies to create drugs and vaccine to help combat COVID-19.

Ritujay Ghosh headshot

Gilead Brings Likely Coronavirus Cure, Pharma Rallies on R&D

Shares of Gilead Science Inc. (GILD) rally on media reports that severe coronavirus patients were responding positively to the company's experimental treatment, remdesivir.

Sanofi and Glaxo Collaborate to Develop Coronavirus Vaccine

Sanofi (SNY) and Glaxo are contributing their proven technologies to develop a coronavirus vaccine, which may be manufactured at large scale.

Ritujay Ghosh headshot

Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up

If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.

BioCryst Begins Study on Galidesivir for Coronavirus Infection

BioCryst (BCRX) starts recruitment for a clinical study on its pipeline candidate galidesivir to treat patients with the deadly coronavirus disease.